Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;41(6):537-545.
doi: 10.1002/phar.2528. Epub 2021 Apr 29.

Management of noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction

Stormi E Gale  1 , Andrew Mardis  2 , Michael E Plazak  3 , Alina Kukin  4 , Brent N Reed  1
Affiliations
Review

Management of noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction

Stormi E Gale et al. Pharmacotherapy. 2021 Jun.

Abstract

Patients with heart failure with reduced ejection fraction often have one or more noncardiovascular comorbidities. The presence of concomitant disease states is associated with worse outcomes, including increased risk of mortality, decreased quality of life, and increased healthcare resource utilization. Additionally, the presence of heart failure with reduced ejection fraction complicates the management of these comorbidities, including varying safety and efficacy of therapies compared to those without heart failure. This article will review the literature on the pharmacologic management of common noncardiovascular comorbidities-including chronic obstructive pulmonary disease, depression, diabetes mellitus, gout, chronic kidney disease, and iron deficiency-in patients with heart failure with reduced ejection fraction, as well as provide recommendations for appropriate treatment selection in this population.

Keywords: chronic kidney diseases; chronic obstructive pulmonary disease; depression; diabetes; gout; heart failure; iron deficiency.

PubMed Disclaimer

References

REFERENCES

    1. Chen Y-T, Wong LL, Liew OW, Richards AM. Heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF): the diagnostic value of circulating microRNAs. Cells. 2019;8(12):1651.
    1. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226-1233.
    1. Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-139.
    1. Lawson CA, Mamas MA, Jones PW, et al. Association of medication intensity and stages of airflow limitation with the risk of hospitalization or death in patients with heart failure and chronic obstructive pulmonary disease. JAMA Netw Open. 2018;1(8):e185489.
    1. Liao K-M, Lin T-Y, Huang Y-B, Kuo C-C, Chen C-Y. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573-2581.

LinkOut - more resources